Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis
Status:
Completed
Trial end date:
2017-08-25
Target enrollment:
Participant gender:
Summary
An open label, safety study to assess the potential for adrenal suppression following maximal
use treatment with DSXS administered twice daily for 28 days in patients with moderate to
severe plaque psoriasis.